NeuroVoices: Beth Stein, MD, on Implications of Newly Approved Pre-Filled Syringe Option for Efgartigimod

Beth Stein, MD, director of neuromuscular diseases at St. Joseph’s Health, shared insights on the impact of a newly approved pre-filled syringe formulation of efgartigimod, highlighting its potential to transform care delivery.:

Source: Neurology Read More

Previous PostFDA Expands Diazepam Nasal Spray Indication to Treat Ages 2 to 5
Next PostHighlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy: Phil Lambert, PhD

NeuroVoices: Beth Stein, MD, on Implications of Newly Approved Pre-Filled Syringe Option for Efgartigimod

Previous PostFDA Expands Diazepam Nasal Spray Indication to Treat Ages 2 to 5

Next PostHighlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy: Phil Lambert, PhD

Related Posts

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

Categories